CULLINAN THERAPEUTICS, INC. Net Income
CULLINAN THERAPEUTICS, INC. (CGEM) reported Net Income of -$219.88 million for the 12-month period ending 2025-12-31, per its DEF 14A filed 2026-04-28.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLoss · last filed 2026-04-28
- CULLINAN THERAPEUTICS, INC. net income (loss) attributable to parent for the quarter ending 2025-12-31 was -$50.71M.
- CULLINAN THERAPEUTICS, INC. net income (loss) attributable to parent for the quarter ending 2025-09-30 was -$50.61M.
- CULLINAN THERAPEUTICS, INC. net income (loss) attributable to parent for the quarter ending 2025-06-30 was -$70.06M.
- CULLINAN THERAPEUTICS, INC. net income (loss) attributable to parent for the quarter ending 2025-03-31 was -$48.50M.
- CULLINAN THERAPEUTICS, INC. net income (loss) attributable to parent for fiscal 2022 was $111.21M.
- CULLINAN THERAPEUTICS, INC. net income (loss) attributable to parent for fiscal 2021 was -$65.57M.
- CULLINAN THERAPEUTICS, INC. net income (loss) attributable to parent for fiscal 2020 was -$51.80M.
| Period end | Net Income (Loss) Attributable to Parent 3 month | Net Income (Loss) Attributable to Parent 6 month | Net Income (Loss) Attributable to Parent 9 month | Net Income (Loss) Attributable to Parent 12 month | Net Income (Loss) Attributable to Parent 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | -$50.71M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-28 | -$101.32M derived: sum of 2 quarters · filed 2026-04-28 | -$171.38M derived: sum of 3 quarters · filed 2026-04-28 | -$219.88M DEF 14A · filed 2026-04-28 | |
| 2025-09-30 | -$50.61M 10-Q · filed 2025-11-06 | -$120.67M derived: sum of 2 quarters · filed 2025-11-06 | -$169.17M 10-Q · filed 2025-11-06 | -$217.00M derived: sum of 4 quarters · filed 2026-04-28 | |
| 2025-06-30 | -$70.06M 10-Q · filed 2025-08-07 | -$118.56M 10-Q · filed 2025-08-07 | -$166.40M derived: sum of 3 quarters · filed 2026-04-28 | -$206.96M derived: sum of 4 quarters · filed 2026-04-28 | |
| 2025-03-31 | -$48.50M 10-Q · filed 2025-05-08 | -$96.34M derived: sum of 2 quarters · filed 2026-04-28 | -$136.90M derived: sum of 3 quarters · filed 2026-04-28 | -$178.93M derived: sum of 4 quarters · filed 2026-04-28 | |
| 2024-12-31 | -$47.84M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-28 | -$88.40M derived: sum of 2 quarters · filed 2026-04-28 | -$130.43M derived: sum of 3 quarters · filed 2026-04-28 | -$167.57M DEF 14A · filed 2026-04-28 | -$167.38M 10-K · filed 2025-02-27 |
| 2024-09-30 | -$40.56M 10-Q · filed 2025-11-06 | -$82.59M derived: sum of 2 quarters · filed 2025-11-06 | -$119.74M 10-Q · filed 2025-11-06 | -$145.48M derived: sum of 4 quarters · filed 2026-04-28 | |
| 2024-06-30 | -$42.03M 10-Q · filed 2025-08-07 | -$79.18M 10-Q · filed 2025-08-07 | -$104.92M derived: sum of 3 quarters · filed 2026-04-28 | -$144.10M derived: sum of 4 quarters · filed 2026-04-28 | |
| 2024-03-31 | -$37.15M 10-Q · filed 2025-05-08 | -$62.89M derived: sum of 2 quarters · filed 2026-04-28 | -$102.07M derived: sum of 3 quarters · filed 2026-04-28 | -$134.29M derived: sum of 4 quarters · filed 2026-04-28 | |
| 2023-12-31 | -$25.74M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-28 | -$64.92M derived: sum of 2 quarters · filed 2026-04-28 | -$97.14M derived: sum of 3 quarters · filed 2026-04-28 | -$155.10M DEF 14A · filed 2026-04-28 | -$153.16M 10-K · filed 2024-03-14 |
| 2023-09-30 | -$39.18M 10-Q · filed 2024-11-07 | -$71.40M derived: sum of 2 quarters · filed 2024-11-07 | -$129.36M 10-Q · filed 2024-11-07 | -$156.14M derived: sum of 4 quarters · filed 2024-11-07 | |
| 2023-06-30 | -$32.21M 10-Q · filed 2024-08-08 | -$90.18M 10-Q · filed 2024-08-08 | -$116.96M derived: sum of 3 quarters · filed 2024-08-08 | -$141.76M derived: sum of 4 quarters · filed 2024-08-08 | |
| 2023-03-31 | -$57.96M 10-Q · filed 2024-05-15 | -$84.74M derived: sum of 2 quarters · filed 2024-05-15 | -$109.55M derived: sum of 3 quarters · filed 2024-05-15 | $65.35M derived: sum of 4 quarters · filed 2024-05-15 | |
| 2022-12-31 | -$26.78M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | -$51.59M derived: sum of 2 quarters · filed 2024-03-14 | $123.31M derived: sum of 3 quarters · filed 2024-03-14 | $111.21M 10-K · filed 2024-03-14 | |
| 2022-09-30 | -$24.80M 10-Q · filed 2023-11-08 | $150.09M derived: sum of 2 quarters · filed 2023-11-08 | $138.00M 10-Q · filed 2023-11-08 | $105.48M derived: sum of 4 quarters · filed 2023-11-08 | |
| 2022-06-30 | $174.90M 10-Q · filed 2023-08-10 | $162.80M 10-Q · filed 2023-08-10 | $130.29M derived: sum of 3 quarters · filed 2023-08-10 | $112.94M derived: sum of 4 quarters · filed 2023-08-10 | |
| 2022-03-31 | -$12.10M 10-Q · filed 2023-05-11 | -$44.61M derived: sum of 2 quarters · filed 2023-05-11 | -$61.96M derived: sum of 3 quarters · filed 2023-05-11 | -$77.60M derived: sum of 4 quarters · filed 2023-05-11 | |
| 2021-12-31 | -$32.51M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | -$49.86M derived: sum of 2 quarters · filed 2023-03-09 | -$65.50M derived: sum of 3 quarters · filed 2023-03-09 | -$65.57M 10-K · filed 2023-03-09 | |
| 2021-09-30 | -$17.35M 10-Q · filed 2022-11-14 | -$32.99M derived: sum of 2 quarters · filed 2022-11-14 | -$33.06M 10-Q · filed 2022-11-14 | -$61.40M derived: sum of 4 quarters · filed 2022-11-14 | |
| 2021-06-30 | -$15.64M 10-Q · filed 2022-08-10 | -$15.71M 10-Q · filed 2022-08-10 | -$44.05M derived: sum of 3 quarters · filed 2022-08-10 | -$53.91M derived: sum of 4 quarters · filed 2022-08-10 | |
| 2021-03-31 | -$70.00K 10-Q · filed 2022-05-16 | -$28.42M derived: sum of 2 quarters · filed 2022-05-16 | -$38.27M derived: sum of 3 quarters · filed 2022-05-16 | -$46.90M derived: sum of 4 quarters · filed 2022-05-16 | |
| 2020-12-31 | -$28.35M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | -$38.20M derived: sum of 2 quarters · filed 2022-03-17 | -$46.83M derived: sum of 3 quarters · filed 2022-03-17 | -$51.80M 10-K · filed 2022-03-17 | |
| 2020-09-30 | -$9.86M 10-Q · filed 2021-11-09 | -$18.48M derived: sum of 2 quarters · filed 2021-11-09 | -$23.45M 10-Q · filed 2021-11-09 | ||
| 2020-06-30 | -$8.62M 10-Q · filed 2021-08-10 | -$13.60M 10-Q · filed 2021-08-10 | |||
| 2020-03-31 | -$4.97M 10-Q · filed 2021-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |